Add-Shop E-Retail Limited
Add-Shop E-Retail Limited (ASRL.BO) Stock Competitors & Peer Comparison
See (ASRL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASRL.BO | ₹7.71 | +0.00% | 219.4M | 12.92 | ₹0.60 | N/A |
| MEDPLUS.BO | ₹848.25 | +1.53% | 102.8B | 49.65 | ₹17.26 | N/A |
| MEDPLUS.NS | ₹848.65 | +1.63% | 102.6B | 49.55 | ₹17.25 | N/A |
| GUJTHEM.BO | ₹313.25 | -1.74% | 34.3B | 71.75 | ₹4.39 | +0.21% |
| SHUKRAPHAR.BO | ₹40.08 | +7.02% | 17.1B | -195.35 | -₹0.20 | +0.05% |
| KPL.BO | ₹1,464.50 | +9.35% | 14.9B | 26.37 | ₹54.51 | N/A |
| SASTASUNDR.NS | ₹281.40 | +0.20% | 9B | 34.66 | ₹8.18 | N/A |
| SASTASUNDR.BO | ₹280.35 | +0.27% | 9B | 34.60 | ₹8.18 | N/A |
| FREDUN.BO | ₹1,640.15 | -0.39% | 7.8B | 23.53 | ₹69.98 | +0.04% |
| BPLPHARMA.BO | ₹1,102.05 | +0.64% | 7.7B | -26.16 | -₹42.81 | +0.09% |
Stock Comparison
ASRL.BO vs MEDPLUS.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, MEDPLUS.BO has a market cap of 102.8B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while MEDPLUS.BO trades at ₹848.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas MEDPLUS.BO's P/E ratio is 49.65. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, ASRL.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check MEDPLUS.BO's competition here
ASRL.BO vs MEDPLUS.NS Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, MEDPLUS.NS has a market cap of 102.6B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while MEDPLUS.NS trades at ₹848.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas MEDPLUS.NS's P/E ratio is 49.55. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, ASRL.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check MEDPLUS.NS's competition here
ASRL.BO vs GUJTHEM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, GUJTHEM.BO has a market cap of 34.3B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while GUJTHEM.BO trades at ₹313.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas GUJTHEM.BO's P/E ratio is 71.75. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, ASRL.BO is more volatile compared to GUJTHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check GUJTHEM.BO's competition here
ASRL.BO vs SHUKRAPHAR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SHUKRAPHAR.BO has a market cap of 17.1B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SHUKRAPHAR.BO trades at ₹40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SHUKRAPHAR.BO's P/E ratio is -195.35. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, ASRL.BO is more volatile compared to SHUKRAPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SHUKRAPHAR.BO's competition here
ASRL.BO vs KPL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, KPL.BO has a market cap of 14.9B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while KPL.BO trades at ₹1,464.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas KPL.BO's P/E ratio is 26.37. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, ASRL.BO is more volatile compared to KPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check KPL.BO's competition here
ASRL.BO vs SASTASUNDR.NS Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SASTASUNDR.NS trades at ₹281.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SASTASUNDR.NS's P/E ratio is 34.66. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, ASRL.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SASTASUNDR.NS's competition here
ASRL.BO vs SASTASUNDR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SASTASUNDR.BO has a market cap of 9B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SASTASUNDR.BO trades at ₹280.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SASTASUNDR.BO's P/E ratio is 34.60. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, ASRL.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SASTASUNDR.BO's competition here
ASRL.BO vs FREDUN.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, FREDUN.BO has a market cap of 7.8B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while FREDUN.BO trades at ₹1,640.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas FREDUN.BO's P/E ratio is 23.53. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, ASRL.BO is more volatile compared to FREDUN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check FREDUN.BO's competition here
ASRL.BO vs BPLPHARMA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, BPLPHARMA.BO has a market cap of 7.7B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while BPLPHARMA.BO trades at ₹1,102.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas BPLPHARMA.BO's P/E ratio is -26.16. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, ASRL.BO is more volatile compared to BPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check BPLPHARMA.BO's competition here
ASRL.BO vs ANUHPHR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ANUHPHR.BO has a market cap of 7.6B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ANUHPHR.BO trades at ₹77.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ANUHPHR.BO's P/E ratio is 18.21. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, ASRL.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ANUHPHR.BO's competition here
ASRL.BO vs PRAVEG.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PRAVEG.BO has a market cap of 6.7B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PRAVEG.BO trades at ₹254.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PRAVEG.BO's P/E ratio is -273.19. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, ASRL.BO is more volatile compared to PRAVEG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PRAVEG.BO's competition here
ASRL.BO vs SGRL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SGRL.BO has a market cap of 6.7B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SGRL.BO trades at ₹508.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SGRL.BO's P/E ratio is 36.85. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, ASRL.BO is more volatile compared to SGRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SGRL.BO's competition here
ASRL.BO vs SUDARSHAN.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SUDARSHAN.BO has a market cap of 6.3B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SUDARSHAN.BO trades at ₹27.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SUDARSHAN.BO's P/E ratio is 31.21. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, ASRL.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check SUDARSHAN.BO's competition here
ASRL.BO vs ALBERTDA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, ASRL.BO is more volatile compared to ALBERTDA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ALBERTDA.BO's competition here
ASRL.BO vs VIKRAMTH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, VIKRAMTH.BO has a market cap of 4.8B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while VIKRAMTH.BO trades at ₹150.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas VIKRAMTH.BO's P/E ratio is 14.01. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, ASRL.BO is more volatile compared to VIKRAMTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check VIKRAMTH.BO's competition here
ASRL.BO vs JENBURPH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, JENBURPH.BO has a market cap of 4.4B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while JENBURPH.BO trades at ₹994.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas JENBURPH.BO's P/E ratio is 13.67. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, ASRL.BO is more volatile compared to JENBURPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check JENBURPH.BO's competition here
ASRL.BO vs TLL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TLL.BO has a market cap of 3.1B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TLL.BO trades at ₹267.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TLL.BO's P/E ratio is 20.74. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, ASRL.BO is more volatile compared to TLL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TLL.BO's competition here
ASRL.BO vs ZENOTECH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ZENOTECH.BO trades at ₹45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ZENOTECH.BO's P/E ratio is 82.33. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, ASRL.BO is more volatile compared to ZENOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ZENOTECH.BO's competition here
ASRL.BO vs GENNEX.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, GENNEX.BO has a market cap of 2.7B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while GENNEX.BO trades at ₹11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas GENNEX.BO's P/E ratio is 15.14. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, ASRL.BO is more volatile compared to GENNEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check GENNEX.BO's competition here
ASRL.BO vs KERALAYUR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, KERALAYUR.BO has a market cap of 2.6B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while KERALAYUR.BO trades at ₹202.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas KERALAYUR.BO's P/E ratio is -11.10. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, ASRL.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check KERALAYUR.BO's competition here
ASRL.BO vs BDH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, BDH.BO has a market cap of 2.4B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while BDH.BO trades at ₹410.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas BDH.BO's P/E ratio is 23.20. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, ASRL.BO is more volatile compared to BDH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check BDH.BO's competition here
ASRL.BO vs SANJIVIN.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SANJIVIN.BO trades at ₹193.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SANJIVIN.BO's P/E ratio is 32.61. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, ASRL.BO is more volatile compared to SANJIVIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SANJIVIN.BO's competition here
ASRL.BO vs SYSCHEM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SYSCHEM.BO trades at ₹49.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SYSCHEM.BO's P/E ratio is 34.03. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, ASRL.BO is more volatile compared to SYSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SYSCHEM.BO's competition here
ASRL.BO vs TRANSCHEM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TRANSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TRANSCHEM.BO trades at ₹181.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TRANSCHEM.BO's P/E ratio is 74.27. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to TRANSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TRANSCHEM.BO's competition here
ASRL.BO vs AMBALALSA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while AMBALALSA.BO trades at ₹26.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas AMBALALSA.BO's P/E ratio is 21.28. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, ASRL.BO is more volatile compared to AMBALALSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check AMBALALSA.BO's competition here
ASRL.BO vs OXYGENTAPH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, OXYGENTAPH.BO has a market cap of 1.9B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while OXYGENTAPH.BO trades at ₹53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas OXYGENTAPH.BO's P/E ratio is -10.71. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, ASRL.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check OXYGENTAPH.BO's competition here
ASRL.BO vs AUROLAB.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while AUROLAB.BO trades at ₹296.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas AUROLAB.BO's P/E ratio is 55.85. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, ASRL.BO is more volatile compared to AUROLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check AUROLAB.BO's competition here
ASRL.BO vs NATCAPSUQ.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while NATCAPSUQ.BO trades at ₹153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas NATCAPSUQ.BO's P/E ratio is -13.64. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, ASRL.BO is less volatile compared to NATCAPSUQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check NATCAPSUQ.BO's competition here
ASRL.BO vs CORALAB.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while CORALAB.BO trades at ₹439.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas CORALAB.BO's P/E ratio is 8.89. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, ASRL.BO is more volatile compared to CORALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check CORALAB.BO's competition here
ASRL.BO vs KIMIABL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, KIMIABL.BO has a market cap of 1.5B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while KIMIABL.BO trades at ₹33.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, ASRL.BO is more volatile compared to KIMIABL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check KIMIABL.BO's competition here
ASRL.BO vs PARNAXLAB.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PARNAXLAB.BO trades at ₹129.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PARNAXLAB.BO's P/E ratio is 13.71. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, ASRL.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PARNAXLAB.BO's competition here
ASRL.BO vs PANCHSHEEL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PANCHSHEEL.BO trades at ₹109.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PANCHSHEEL.BO's P/E ratio is 11.94. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, ASRL.BO is more volatile compared to PANCHSHEEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PANCHSHEEL.BO's competition here
ASRL.BO vs SMRUTHIORG.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SMRUTHIORG.BO trades at ₹113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SMRUTHIORG.BO's P/E ratio is 27.94. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, ASRL.BO is more volatile compared to SMRUTHIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SMRUTHIORG.BO's competition here
ASRL.BO vs PHARMAID.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PHARMAID.BO has a market cap of 1.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PHARMAID.BO trades at ₹31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PHARMAID.BO's P/E ratio is -9.92. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, ASRL.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check PHARMAID.BO's competition here
ASRL.BO vs LACTOSE.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while LACTOSE.BO trades at ₹97.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas LACTOSE.BO's P/E ratio is 42.06. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, ASRL.BO is more volatile compared to LACTOSE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check LACTOSE.BO's competition here
ASRL.BO vs TYCHE.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TYCHE.BO trades at ₹117.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TYCHE.BO's P/E ratio is 11.86. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, ASRL.BO is more volatile compared to TYCHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TYCHE.BO's competition here
ASRL.BO vs DENISCHEM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, DENISCHEM.BO has a market cap of 1B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while DENISCHEM.BO trades at ₹75.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas DENISCHEM.BO's P/E ratio is 14.54. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, ASRL.BO is more volatile compared to DENISCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check DENISCHEM.BO's competition here
ASRL.BO vs MERCURYLAB.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, MERCURYLAB.BO has a market cap of 1B. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while MERCURYLAB.BO trades at ₹808.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas MERCURYLAB.BO's P/E ratio is 21.34. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, ASRL.BO is more volatile compared to MERCURYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check MERCURYLAB.BO's competition here
ASRL.BO vs MAKERSL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, MAKERSL.BO has a market cap of 947.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while MAKERSL.BO trades at ₹155.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas MAKERSL.BO's P/E ratio is 77.96. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, ASRL.BO is more volatile compared to MAKERSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check MAKERSL.BO's competition here
ASRL.BO vs SOURCENTRL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SOURCENTRL.BO has a market cap of 849.4M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SOURCENTRL.BO trades at ₹125.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SOURCENTRL.BO's P/E ratio is 28.56. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, ASRL.BO is more volatile compared to SOURCENTRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SOURCENTRL.BO's competition here
ASRL.BO vs BIBCL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, BIBCL.BO has a market cap of 769.5M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while BIBCL.BO trades at ₹17.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas BIBCL.BO's P/E ratio is -4.80. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ASRL.BO is more volatile compared to BIBCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check BIBCL.BO's competition here
ASRL.BO vs CONCORD.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, CONCORD.BO has a market cap of 746.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while CONCORD.BO trades at ₹78.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas CONCORD.BO's P/E ratio is 129.29. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, ASRL.BO is more volatile compared to CONCORD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check CONCORD.BO's competition here
ASRL.BO vs BACPHAR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, BACPHAR.BO has a market cap of 713.8M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while BACPHAR.BO trades at ₹48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas BACPHAR.BO's P/E ratio is 134.41. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to BACPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check BACPHAR.BO's competition here
ASRL.BO vs SUNLOC.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SUNLOC.BO has a market cap of 661.7M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SUNLOC.BO trades at ₹65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SUNLOC.BO's P/E ratio is 23.13. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to SUNLOC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SUNLOC.BO's competition here
ASRL.BO vs PHRMASI.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PHRMASI.BO has a market cap of 634.9M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PHRMASI.BO trades at ₹91.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PHRMASI.BO's P/E ratio is 3.58. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, ASRL.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PHRMASI.BO's competition here
ASRL.BO vs GODAVARI.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, GODAVARI.BO has a market cap of 595.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while GODAVARI.BO trades at ₹77.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas GODAVARI.BO's P/E ratio is -86.91. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, ASRL.BO is more volatile compared to GODAVARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check GODAVARI.BO's competition here
ASRL.BO vs PANJON.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PANJON.BO has a market cap of 502.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PANJON.BO trades at ₹28.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PANJON.BO's P/E ratio is 117.04. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, ASRL.BO is more volatile compared to PANJON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PANJON.BO's competition here
ASRL.BO vs VISTAPH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, VISTAPH.BO has a market cap of 418.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while VISTAPH.BO trades at ₹6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas VISTAPH.BO's P/E ratio is -5.96. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, ASRL.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check VISTAPH.BO's competition here
ASRL.BO vs VRL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, VRL.BO has a market cap of 416.7M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while VRL.BO trades at ₹131.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas VRL.BO's P/E ratio is 11.15. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, ASRL.BO is more volatile compared to VRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check VRL.BO's competition here
ASRL.BO vs SHELTER.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SHELTER.BO has a market cap of 410.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SHELTER.BO trades at ₹35.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SHELTER.BO's P/E ratio is 6.56. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, ASRL.BO is more volatile compared to SHELTER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SHELTER.BO's competition here
ASRL.BO vs VEERHEALTH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, VEERHEALTH.BO has a market cap of 397.4M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while VEERHEALTH.BO trades at ₹19.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas VEERHEALTH.BO's P/E ratio is 82.79. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is less volatile compared to VEERHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check VEERHEALTH.BO's competition here
ASRL.BO vs ROOPAIND.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ROOPAIND.BO has a market cap of 348.3M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ROOPAIND.BO trades at ₹44.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ROOPAIND.BO's P/E ratio is 18.07. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, ASRL.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check ROOPAIND.BO's competition here
ASRL.BO vs SANDUPHQ.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SANDUPHQ.BO has a market cap of 340.5M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SANDUPHQ.BO trades at ₹35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SANDUPHQ.BO's P/E ratio is 20.98. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, ASRL.BO is more volatile compared to SANDUPHQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SANDUPHQ.BO's competition here
ASRL.BO vs DECCAN.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, DECCAN.BO has a market cap of 309M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while DECCAN.BO trades at ₹13.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas DECCAN.BO's P/E ratio is 23.14. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ASRL.BO is more volatile compared to DECCAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check DECCAN.BO's competition here
ASRL.BO vs MEDICAPQ.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, MEDICAPQ.BO has a market cap of 299.3M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while MEDICAPQ.BO trades at ₹25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas MEDICAPQ.BO's P/E ratio is -5.31. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, ASRL.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check MEDICAPQ.BO's competition here
ASRL.BO vs ANG.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ANG.BO has a market cap of 296.8M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ANG.BO trades at ₹23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ANG.BO's P/E ratio is -2.43. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, ASRL.BO is more volatile compared to ANG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ANG.BO's competition here
ASRL.BO vs GUJTERC.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, GUJTERC.BO has a market cap of 287.9M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while GUJTERC.BO trades at ₹39.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas GUJTERC.BO's P/E ratio is -20.75. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, ASRL.BO is more volatile compared to GUJTERC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check GUJTERC.BO's competition here
ASRL.BO vs CRSTCHM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, CRSTCHM.BO has a market cap of 270.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while CRSTCHM.BO trades at ₹91.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas CRSTCHM.BO's P/E ratio is 13.34. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, ASRL.BO is more volatile compared to CRSTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check CRSTCHM.BO's competition here
ASRL.BO vs TRIMURTHI.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TRIMURTHI.BO's competition here
ASRL.BO vs ISHITADR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ISHITADR.BO has a market cap of 207M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ISHITADR.BO trades at ₹69.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ISHITADR.BO's P/E ratio is 23.31. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, ASRL.BO is more volatile compared to ISHITADR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ISHITADR.BO's competition here
ASRL.BO vs CHEMOPH.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, ASRL.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check CHEMOPH.BO's competition here
ASRL.BO vs ZENITHHE.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ZENITHHE.BO has a market cap of 180M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ZENITHHE.BO trades at ₹3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ZENITHHE.BO's P/E ratio is -335.00. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, ASRL.BO is more volatile compared to ZENITHHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ZENITHHE.BO's competition here
ASRL.BO vs ZENLABS.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ZENLABS.BO has a market cap of 136.1M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ZENLABS.BO trades at ₹20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ZENLABS.BO's P/E ratio is -7.36. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, ASRL.BO is more volatile compared to ZENLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check ZENLABS.BO's competition here
ASRL.BO vs NORRIS.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, NORRIS.BO has a market cap of 135.4M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while NORRIS.BO trades at ₹13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, ASRL.BO is more volatile compared to NORRIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check NORRIS.BO's competition here
ASRL.BO vs EMMESSA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, EMMESSA.BO has a market cap of 126.4M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while EMMESSA.BO trades at ₹26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas EMMESSA.BO's P/E ratio is 57.50. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to EMMESSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check EMMESSA.BO's competition here
ASRL.BO vs CHCL.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, ASRL.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check CHCL.BO's competition here
ASRL.BO vs COLINZ.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, COLINZ.BO has a market cap of 116M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while COLINZ.BO trades at ₹45.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas COLINZ.BO's P/E ratio is 23.49. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, ASRL.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check COLINZ.BO's competition here
ASRL.BO vs DESHRAK.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, DESHRAK.BO has a market cap of 113.7M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while DESHRAK.BO trades at ₹25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas DESHRAK.BO's P/E ratio is 30.90. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check DESHRAK.BO's competition here
ASRL.BO vs PARMAX.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PARMAX.BO has a market cap of 113.7M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PARMAX.BO trades at ₹30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PARMAX.BO's P/E ratio is -3.90. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PARMAX.BO's ROE of +2.05%. Regarding short-term risk, ASRL.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check PARMAX.BO's competition here
ASRL.BO vs SHAMROIN.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, ASRL.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check SHAMROIN.BO's competition here
ASRL.BO vs TRINITYLEA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TRINITYLEA.BO has a market cap of 110.4M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TRINITYLEA.BO trades at ₹13.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TRINITYLEA.BO's P/E ratio is -465.00. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, ASRL.BO is more volatile compared to TRINITYLEA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TRINITYLEA.BO's competition here
ASRL.BO vs BERLDRG.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, BERLDRG.BO has a market cap of 106.9M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while BERLDRG.BO trades at ₹21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas BERLDRG.BO's P/E ratio is 702.33. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, ASRL.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check BERLDRG.BO's competition here
ASRL.BO vs HINDBIO.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, HINDBIO.BO has a market cap of 85M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while HINDBIO.BO trades at ₹8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas HINDBIO.BO's P/E ratio is 55.27. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, ASRL.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check HINDBIO.BO's competition here
ASRL.BO vs ADLINE.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, ADLINE.BO has a market cap of 82M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while ADLINE.BO trades at ₹14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, ASRL.BO is less volatile compared to ADLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check ADLINE.BO's competition here
ASRL.BO vs VIVANZA.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, VIVANZA.BO has a market cap of 81.6M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while VIVANZA.BO trades at ₹2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas VIVANZA.BO's P/E ratio is -25.50. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, ASRL.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check VIVANZA.BO's competition here
ASRL.BO vs EVOQ.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, EVOQ.BO has a market cap of 80.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while EVOQ.BO trades at ₹3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas EVOQ.BO's P/E ratio is 4.54. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check EVOQ.BO's competition here
ASRL.BO vs DECIPHER.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, DECIPHER.BO has a market cap of 75.8M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while DECIPHER.BO trades at ₹7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas DECIPHER.BO's P/E ratio is -0.94. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, ASRL.BO is more volatile compared to DECIPHER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check DECIPHER.BO's competition here
ASRL.BO vs GANGAPHARM.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ASRL.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check GANGAPHARM.BO's competition here
ASRL.BO vs TIAANC.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TIAANC.BO has a market cap of 63.2M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TIAANC.BO trades at ₹6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TIAANC.BO's P/E ratio is -61.50. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ASRL.BO is more volatile compared to TIAANC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TIAANC.BO's competition here
ASRL.BO vs KOBO.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, KOBO.BO has a market cap of 60M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while KOBO.BO trades at ₹2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas KOBO.BO's P/E ratio is -1.19. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to KOBO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check KOBO.BO's competition here
ASRL.BO vs PATIDAR.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, PATIDAR.BO has a market cap of 52M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while PATIDAR.BO trades at ₹9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas PATIDAR.BO's P/E ratio is -19.29. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, ASRL.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check PATIDAR.BO's competition here
ASRL.BO vs WELCURE.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, WELCURE.BO has a market cap of 37.1M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while WELCURE.BO trades at ₹0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas WELCURE.BO's P/E ratio is 1.14. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, ASRL.BO is more volatile compared to WELCURE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check WELCURE.BO's competition here
ASRL.BO vs TMTIND-B1.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while TMTIND-B1.BO trades at ₹6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ASRL.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRL.BO.Check TMTIND-B1.BO's competition here
ASRL.BO vs FABINO.BO Comparison February 2026
ASRL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRL.BO stands at 219.4M. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, ASRL.BO is priced at ₹7.71, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRL.BO currently has a P/E ratio of 12.92, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, ASRL.BO's ROE is +0.01%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ASRL.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRL.BO.Check FABINO.BO's competition here